Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALISADE BIO, INC.PALI · Entity 5803 | Director | June 10, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALISADE BIO, INC.
Report date June 10, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 613,355 |
Ending reported balance
After 2026-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-10 · Grant · Acquired 592,300 · Balance 593,155 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. Row 2 · 2026-06-10 · Exercise / conversion · Acquired 20,200 · Balance 613,355 F2: The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 40,400 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Exercise / conversion · Disposed 20,200 · Balance 40,400 F3: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date.
F2: The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026.
F3: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 13, 2026 00:14 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 20,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-028574 · ownership.xml · derivative · entry 3 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,400 Underlying: Common Stock · 20,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. F3 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. F3 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| June 10, 2026 Filed Jun 13, 2026 00:14 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock | 20,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-028574 · ownership.xml · nonDerivative · entry 2 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. F2 · price: The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. Read SEC document |
| June 10, 2026 Filed Jun 13, 2026 00:14 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock | 592,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-028574 · ownership.xml · nonDerivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 593,155 F1 · kind: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 21:45 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 510,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-017479 · ownership.xml · derivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 510,700 Underlying: Common Stock · 510,700 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. F2 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, which shall be satisfied on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, which shall be satisfied on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| October 06, 2025 Filed Nov 7, 2025 01:20 UTC Amendment | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 60,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-021133 · ownership.xml · derivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,600 Underlying: Common Stock · 60,600 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan (the "Plan") to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. F2 · shares: This amended Form 4 is being filed to correct the previously reported grant amount of 510,700 RSUs to the Reporting Person. The Issuer has rescinded the grant of 450,100 RSUs of the previously reported grant of 510,700 RSUs. F3 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. F3 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 13:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantPhantom Units · Derivative | 18,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-012692 · ownership.xml · derivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,800 Underlying: Common Stock · 18,800 shares Expires not disclosed F1 · derivative.exercise_price: Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock. F2 · derivative.exercise_date: The Phantom Units vest in three equal annual installments beginning on August 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. F3 · derivative.exercise_date: Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service with the Issuer; (b) a Liquidity Change in Control (as defined in the Phantom Unit Plan) of the Issuer; or (c) 7th anniversary of the grant date. F2 · derivative.expiration_date: The Phantom Units vest in three equal annual installments beginning on August 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. F3 · derivative.expiration_date: Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service with the Issuer; (b) a Liquidity Change in Control (as defined in the Phantom Unit Plan) of the Issuer; or (c) 7th anniversary of the grant date. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionComon Stock, par value $0.01 | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-047364 · ownership.xml · nonDerivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the issuance of common stock upon the full vesting and settlement of outstanding restricted stock units granted on November 21, 2023. F1 · price: Represents the issuance of common stock upon the full vesting and settlement of outstanding restricted stock units granted on November 21, 2023. Read SEC document |
| July 11, 2024 Filed Jul 16, 2024 00:19 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 2,100 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001493152-24-027911 · ownership.xml · derivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires 2034-07-11 F1 · security: Represents partial compensation for services as a director pursuant to Issuer's non-employee director compensation policy, consisting of 2,100 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F3 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 01:41 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionComon Stock, par value $0.01 | 465 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-023614 · ownership.xml · nonDerivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 6,880 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-23-042658 · ownership.xml · derivative · entry 2 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,880 Underlying: Common Stock · 6,880 shares Expires 2033-11-21 F1 · security: Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F5 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 5,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-042658 · ownership.xml · derivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,820 Underlying: Common Stock · 5,820 shares Expires not disclosed F1 · security: Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F3 · security: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_price: The grants vest fully on the one (1) year anniversary of the grant date. F3 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: N/A. Read SEC document |
| June 11, 2023 Filed Jun 13, 2023 22:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 9,580 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-23-021127 · ownership.xml · derivative · entry 2 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,580 Underlying: Common Stock · 9,580 shares Expires 2033-06-11 F1 · security: Represents partial compensation for services rendered as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from the Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 1,880 restricted stock units and 2,580 common stock purchase options as a discretionary grant. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F5 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| June 11, 2023 Filed Jun 13, 2023 22:44 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 6,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-021127 · ownership.xml · derivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,980 Underlying: Common Stock · 6,980 shares Expires not disclosed F1 · security: Represents partial compensation for services rendered as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from the Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 1,880 restricted stock units and 2,580 common stock purchase options as a discretionary grant. F3 · security: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_price: The grants vest fully on the one (1) year anniversary of the grant date. F3 · shares: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: N/A Read SEC document |
| November 18, 2021 Filed Feb 10, 2022 23:11 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (right to buy) · Derivative | 48,340 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-008569 · doc4.xml · derivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,340 Underlying: Common Stock · 48,340 shares Expires 2032-11-17 F1 · derivative.exercise_date: 25% of the shares of Common Stock subject to the Option shall vest on each quarterly anniversary of the grant date over a one-year period. Read SEC document |
| April 01, 2021 Filed Apr 26, 2021 23:51 UTC | PALISADE BIO, INC. SNCA · Entity 5803 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-002775 · ownership.xml · derivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · security: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F2 · security: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · shares: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F2 · shares: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · derivative.exercise_date: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F1 · derivative.expiration_date: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:49 UTC | PALISADE BIO, INC. SNCA · Entity 5803 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-002465 · ownership.xml · derivative · entry 1 Wei Binxian · CIK 0001773586 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · security: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21. F2 · security: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · shares: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21. F2 · shares: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · derivative.exercise_date: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21. F3 · derivative.expiration_date: N/A Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.